EU medtech legislation recast is still on
This article was originally published in Clinica
European Commissioner for Health and Consumer Policy John Dalli has confirmed that a recast of the European medical device directives is still very much on the cards.
You may also be interested in...
An ambitious action plan drawn by an EU task force, if implemented on a priority basis by the European Commission, could increase the EU’s capacity to advise on, assess and analyze big data.
Swissmedic will scale back its review procedure for certain anti-infectives if the indications for which approval is being sought are identical to those approved in the EU or the US.
Based on the operational experience gained using the new international standard for reporting suspected adverse reactions in EudraVigilance, the EU has decided to set a date for its mandatory use.